Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors.
RNA splicing is required to remove introns from pre-mRNA, and alternative splicing generates protein diversity. Topoisomerase I (Top1) has been shown to be coupled with splicing by regulating serine/arginine-rich splicing proteins. Prior studies on isolated genes also showed that Top1 poisoning by camptothecin (CPT), which traps Top1 cleavage complexes (Top1cc), can alter RNA splicing. Here, we tested the effect of Top1 inhibition on splicing at the genome-wide level in human colon carcinoma HCT116 and breast carcinoma MCF7 cells. The RNA of HCT116 cells treated with CPT for various times was analyzed with ExonHit Human Splice Array. Unlike other exon array platforms, the ExonHit arrays include junction probes that allow the detection of splice variants with high sensitivity and specificity. We report that CPT treatment preferentially affects the splicing of splicing-related factors, such as RBM8A, and generates transcripts coding for inactive proteins lacking key functional domains. The splicing alterations induced by CPT are not observed with cisplatin or vinblastine and are not simply due to reduced Top1 activity, as Top1 downregulation by short interfering RNA did not alter splicing like CPT treatment. Inhibition of RNA polymerase II (Pol II) hyperphosphorylation by 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB) blocked the splicing alteration induced by CPT, which suggests that the rapid Pol II hyperphosphorylation induced by CPT interferes with normal splicing. The preferential effect of CPT on genes encoding splicing factors may explain the abnormal splicing of a large number of genes in response to Top1cc.
Solier
Stéphanie
S
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.
Barb
Jennifer
J
Zeeberg
Barry R
BR
Varma
Sudhir
S
Ryan
Mike C
MC
Kohn
Kurt W
KW
Weinstein
John N
JN
Munson
Peter J
PJ
Pommier
Yves
Y
D017398:Alternative Splicing / Q000187:drug effects / Q000235:genetics; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002166:Camptothecin / Q000494:pharmacology; D002945:Cisplatin / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000235:genetics; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000506:poisoning*; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000235:genetics; D015536:Down-Regulation / Q000187:drug effects; D005091:Exons / Q000187:drug effects / Q000235:genetics; D014644:Genetic Variation; D055106:Genome-Wide Association Study / Q000379:methods*; D006801:Humans; D015233:Models, Statistical; D010766:Phosphorylation; D012319:RNA Polymerase II / Q000187:drug effects / Q000378:metabolism; D012326:RNA Splicing / Q000235:genetics; D034741:RNA, Small Interfering / Q000187:drug effects / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014747:Vinblastine / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D004268:DNA-Binding Proteins; D034741:RNA, Small Interfering; D014747:Vinblastine; D012319:RNA Polymerase II; D004264:DNA Topoisomerases, Type I; D002945:Cisplatin; D002166:Camptothecin
Chem Biol. 2010 May 28;17(5):421-33
20534341
Nucleic Acids Res. 2005 Mar 10;33(5):e47
15760843
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
12042765
Med Sci (Paris). 2005 Mar;21(3):253-60
15745698
Biochem Biophys Res Commun. 2005 Jun 3;331(2):398-403
15850773
Annu Rev Biochem. 2001;70:369-413
11395412
Trends Biochem Sci. 2010 Sep;35(9):497-504
20418102
Nat Genet. 2002 Jan;30(1):13-9
11753382
J Cell Biol. 2001 Jul 9;154(1):25-32
11448987
Nucleic Acids Res. 2008 Jul;36(12):4128-36
18550580
J Mol Biol. 2008 Sep 5;381(3):540-9
18588899
Nature. 1996 May 2;381(6577):80-2
8609994
Genomics. 2000 Oct 1;69(1):54-62
11013075
Nat Rev Cancer. 2006 Oct;6(10):789-802
16990856
BMC Bioinformatics. 2007 Mar 05;8:75
17338820
Cell. 2009 May 15;137(4):600-2
19450507
Mol Cancer Ther. 2008 Jun;7(6):1398-409
18566212
EMBO J. 2010 Jul 7;29(13):2126-34
20526281
Prog Nucleic Acid Res Mol Biol. 2006;81:179-229
16891172
Nature. 1993 Sep 16;365(6443):227-32
8396729
J Biol Chem. 1985 Nov 25;260(27):14873-8
2997227
Genes Dev. 2006 Nov 1;20(21):2922-36
17079683
Mol Cell Biol. 2003 Apr;23(7):2341-50
12640119
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11508-12
8265582
Genome Res. 2003 Aug;13(8):1863-72
12902380
Biochim Biophys Acta. 2000 Jul 24;1492(2-3):465-9
11004516
Mol Cell Biol. 2009 Jan;29(1):68-82
18955500
Nature. 2010 Jan 28;463(7280):457-63
20110989
Circ Res. 2009 Mar 13;104(5):589-99
19168442
Mol Cancer Res. 2004 Jan;2(1):53-61
14757846
Cancer Res. 2003 Dec 1;63(23):8203-11
14678976
Science. 1994 Jul 29;265(5172):615-21
8036511
Mol Cell. 2003 Aug;12(2):525-32
14536091
Cancer Res. 2001 Sep 15;61(18):6876-84
11559564
Nat Struct Mol Biol. 2006 Sep;13(9):815-22
16921380
FEBS Lett. 2008 Jan 23;582(2):372-8
18166155
J Biol Chem. 2007 Aug 3;282(31):22544-50
17562711
J Mol Med (Berl). 1997 Nov-Dec;75(11-12):786-800
9428609
J Mol Biol. 2002 Sep 27;322(4):677-86
12270705
Cell. 2009 May 15;137(4):708-20
19450518
J Mol Biol. 2006 Mar 17;357(1):127-38
16427078
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7024-7
2823250
BMC Bioinformatics. 2005 Jul 05;6:168
15998470
Mol Cell. 1999 Jun;3(6):697-705
10394358
J Biol Chem. 2008 Aug 22;283(34):23200-8
18556653
Nat Rev Mol Cell Biol. 2009 Nov;10(11):741-54
19773805
Nucleic Acids Res. 2010 Jan;38(1):159-71
19854946
J Biol Chem. 2008 Jul 18;283(29):19991-8
18495665
Nat Struct Mol Biol. 2006 Nov;13(11):973-80
17028590
Biochim Biophys Acta. 2010 Dec;1806(2):240-50
20600630